

MEDICAL ASSISTANCE BULLETIN

ISSUE DATE

EFFECTIVE DATE

September 29, 2023

October 1, 2023

NUMBER

01-23-25, 08-23-28, 09-23-24, 10-23-11, 24-23-21, 31-23-26, 33-23-22

SUBJECT

Addition of Procedure Codes for Vaccine
Administration

BY

Sally A. Kozak, Deputy Secretary

Sally h. Kozel

Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to advise providers that the Department of Human Services (Department) is adding procedure codes to the Medical Assistance (MA) Program Fee Schedule for vaccine administration.

SCOPE:

This bulletin applies to all outpatient hospital-based medical clinics, independent medical/surgical clinics, pharmacies, physicians, certified registered nurse practitioners, physician assistants, and certified nurse midwives enrolled in the MA Program who may administer vaccines to MA beneficiaries in the fee-for-service delivery system. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any coding or billing questions.

BACKGROUND/DISCUSSION:

The Centers for Medicare & Medicaid Services (CMS) issued State Health Official Letter # 23-003 on June 27, 2023, regarding mandatory Medicaid coverage and reimbursement of vaccines for adults as required by Section 11405 of the Inflation Reduction Act (Pub. L. 117-169).

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

Fee-for-service provider service center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx.

Beginning October 1, 2023, the MA Program will provide coverage, without cost sharing, for vaccines and their administration, when approved by the U.S. Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices (ACIP), as described in Section 1905(a)(13)(B) of the Social Security Act.

Historically, the Department has covered the ACIP recommended vaccines on the adult immunization schedule. The procedure codes being added are based on other ACIP recommendations, such as vaccines recommended due to travel, occupation or shared clinical decision making.

PROCEDURE:

The Department is adding the following procedure codes to the MA Program Fee Schedule to be used for vaccine administration. Providers should follow the ACIP recommendations and the package insert to determine the correct population, dosage and instructions for administration of all vaccines.

Procedure Code	National Code Description	Effective Date	MA Fee
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	10/1/23	\$10.00
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	10/1/23	\$10.00
90581	Anthrax vaccine, for subcutaneous or intramuscular use	10/1/23	\$10.00
90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	1/1/24	\$10.00
90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	1/1/24	\$10.00
90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	10/1/23	\$10.00
90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	10/1/23	\$10.00
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	1/1/24	\$10.00
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	10/1/23	\$10.00
90758	Zaire ebolavirus vaccine, live, for intramuscular use	10/1/23	\$10.00

NOTE: Provider type 10, specialty 100 (physician assistant) is included because physician assistants can be identified as the rendering provider pursuant to MA Bulletin 01-22-05, 08-22-05, 09-22-04, 10-22-01, 31-22-05, entitled "Billing Procedure Update for Certified Registered Nurse Practitioners and Physician Assistants"

(https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022010701.pdf).

Procedure codes 90589, 90623 and 90683 are effective January 1, 2024, to coincide with the effective date of those codes as specified by the American Medical Association, anticipating the FDA approval of the vaccine. If the FDA approval occurs prior to that date and the provider determines that the vaccine is a medically necessary, the provider may use the procedure code 90749 (Unlisted vaccine/toxoid) to bill for the administration of the vaccine.

The attachment includes the list of procedure code updates from above chart, which includes the procedure code, code description, provider type, provider specialty, place of service, effective date, and MA fee. Providers are to utilize the codes as outlined in this Bulletin and in the attachment. Providers may also access the online version of the MA Program Fee Schedule on the Department's website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the DHS Pharmacy Services Covered Drugs Search Tool on the Department's website at:

https://www.humanservices.state.pa.us/CoveredDrugs/CoveredDrugs/Index.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of vaccines by a pharmacist, refer to MA Bulletin 01-21-19, "Vaccine Administration by Pharmacists – Pharmacy Services." The bulletin is available on the Department's website at:

https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2021123001.pdf.

RESOURCES:

Advisory Committee on Immunization Practices https://www.cdc.gov/vaccines/hcp/acip-recs/index.html

Centers for Disease Control and Prevention Vaccines for Children Program https://www.cdc.gov/vaccines/programs/vfc/about/index.html

Centers for Disease Control and Prevention Vaccine Information for Adults https://www.cdc.gov/vaccines/adults/index.html

Pennsylvania Department of Health https://www.health.pa.gov/topics/programs/immunizations/Pages/Immunizations.aspx

U.S. Food and Drug Administration – Vaccines Licensed for Use

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

ATTACHMENT:

Updates to the Medical Assistance Program Fee Schedule for Vaccine Administration

	Updates to the Medical Assistance Program Fee Schedule for Vaccine Administration										
Procedure Code	Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	Effective Date	MA Fee	MA Units	Limits	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	01	183	22			10/1/2023	\$10.00	per administration	once per day	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	08	082	49			10/1/2023	\$10.00	per administration	once per day	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	09	All	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	10	100	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	24	247	11			10/1/2023	\$10.00	per administration	once per day	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	31	All	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	33	335	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	01	183	22			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	08	082	49			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	09	All	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	10	100	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	24	247	11			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	31	All	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	33	335	11, 12, 27			10/1/2023	\$10.00	per administration	once per day	

	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	01	183	22	10/1/2023	\$10.00	administration	day
	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	08	082	49	10/1/2023	\$10.00	administration	day
	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	09	All	11, 12, 27	10/1/2023	\$10.00	administration	day
	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	10	100	11, 12, 27	10/1/2023	\$10.00	administration	day
	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	24	247	11	10/1/2023	\$10.00	administration	day
	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	31	All	11, 12, 27	10/1/2023	\$10.00	administration	day
	Anthrax vaccine, for subcutaneous or						per	once per
90581	intramuscular use	33	335	11, 12, 27	10/1/2023	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	01	183	22	1/1/2024	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	08	082	49	1/1/2024	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	09	All	11, 12, 27	1/1/2024	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	10	100	11, 12, 27	1/1/2024	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	24	247	11	1/1/2024	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	31	All	11, 12, 27	1/1/2024	\$10.00	administration	day
	Chikungunya virus vaccine, live						per	once per
90589	attenuated, for intramuscular use	33	335	11, 12, 27	1/1/2024	\$10.00	administration	day
	Meningococcal pentavalent vaccine,							
	conjugated Men A, C, W, Y – tetanus							
	toxoid carrier, and Men B-FHbp, for						per	once per
90623	intramuscular use	01	183	22	1/1/2024	\$10.00	administration	day
	Meningococcal pentavalent vaccine,							
	conjugated Men A, C, W, Y – tetanus							
	toxoid carrier, and Men B-FHbp, for						per	once per
90623	intramuscular use	80	082	49	1/1/2024	\$10.00	administration	day
	Meningococcal pentavalent vaccine,							
	conjugated Men A, C, W, Y – tetanus							
	toxoid carrier, and Men B-FHbp, for						per	once per
90623	intramuscular use	09	All	11, 12, 27	1/1/2024	\$10.00	administration	day
	Meningococcal pentavalent vaccine,							
	conjugated Men A, C, W, Y – tetanus							
	toxoid carrier, and Men B-FHbp, for						per	once per
90623	intramuscular use	10	100	11, 12, 27	1/1/2024	\$10.00	administration	day

Meningococcal pentavalent vaccine								
toxoid carrier, and Men B-FHbp, for							per	once per
intramuscular use	24	247	11		1/1/2024	\$10.00	administration	day
Meningococcal pentavalent vaccine,								
conjugated Men A, C, W, Y – tetanus								
toxoid carrier, and Men B-FHbp, for							per	once per
intramuscular use	31	All	11, 12, 27		1/1/2024	\$10.00	administration	day
Meningococcal pentavalent vaccine,								
•							per	once per
	33	335	11, 12, 27		1/1/2024	\$10.00	administration	day
, , , ,								
1					40440000	*	<u>.</u>	once per
	01	183	22		10/1/2023	\$10.00	administration	day
1	00	000	40		10/1/2022	# 40.00	•	once per
	08	082	49		10/1/2023	\$10.00	administration	day
							nor	onco nor
	00	Δ11	11 12 27		10/1/2023	¢ 10 00	-	once per day
	09	All	11, 12, 21		10/1/2023	φ10.00	aummstration	uay
							ner	once per
	10	100	11 12 27		10/1/2023	\$10.00	-	day
	10	100	11, 12, 21		10/1/2020	ψ10.00	administration	day
, , , ,							per	once per
I I	24	247	11		10/1/2023	\$10.00	-	day
						7 10100		
							per	once per
use	31	All	11, 12, 27		10/1/2023	\$10.00	administration	day
Respiratory syncytial virus vaccine,								
preF, subunit, bivalent, for intramuscular							per	once per
use	33	335	11, 12, 27		10/1/2023	\$10.00	administration	day
Respiratory syncytial virus vaccine,								
preF, recombinant, subunit, adjuvanted,							per	once per
	01	183	22		10/1/2023	\$10.00	administration	day
							per	once per
	80	082	49		10/1/2023	\$10.00	administration	day
	22		44 40 07		40/4/0000	040.00	-	once per
	09	All	11, 12, 27		10/1/2023	\$10.00	administration	day
, , , ,		1					10 - 11	
for intramuscular use	10	100	11 10 07		10/1/2022	# 40.00	-	once per
nor muanuscriar use	10	100	11, 12, 27		10/1/2023	\$10.00	administration	day
Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted,							per	once per
	intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular us	conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y – tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Respiratory syncytial virus	conjugated Men A, C, W, Y - tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y - tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y - tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y - tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 01 183 22 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 08 082 49 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 10 100 11, 12, 27 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 10 100 11, 12, 27 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 24 247 11 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 31 All 11, 12, 27 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 31 All 11, 12, 27 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 33 335 11, 12, 27 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use 31 All 11, 12, 27 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use 09 All 11, 12, 27 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use 08 082 49 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use 09 All 11, 12, 27	Conjugated Men A, C, W, Y - tetanus	Conjugated Men A, C, W, Y - tetanus toxoid carrier; and Men B-FHbp, for intramuscular use 24 247 11 1/1/2024 \$10.00	Conjugated Men A. C. W. Y Tetanus toxoid carrier, and Men B-FHbp, for intramuscular use 24 247 11 1/1/2024 \$10.00 administration Per intramuscular use 24 247 11 1/1/2024 \$10.00 administration Per intramuscular use 31 All 11, 12, 27 1/1/2024 \$10.00 administration Per intramuscular use 31 All 11, 12, 27 1/1/2024 \$10.00 administration Per intramuscular use 33 335 11, 12, 27 1/1/2024 \$10.00 administration Per intramuscular use 33 335 11, 12, 27 1/1/2024 \$10.00 administration Per intramuscular use 33 335 11, 12, 27 1/1/2023 \$10.00 administration Per intramuscular use 33 335 11, 12, 27 1/1/2023 \$10.00 administration Per intramuscular use 34 32 34 34 34 34 34 34

90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	31	All	11, 12, 27	10/1/2023	\$10.00	per administration	once per day
90079	Respiratory syncytial virus vaccine,	31	All	11, 12, 21	10/1/2023	\$10.00	aummstration	uay
90679	preF, recombinant, subunit, adjuvanted, for intramuscular use	33	335	11, 12, 27	10/1/2023	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	01	183	22	1/1/2024	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	08	082	49	1/1/2024	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	09	All	11, 12, 27	1/1/2024	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	10	100	11, 12, 27	1/1/2024	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	24	247	11	1/1/2024	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	31	All	11, 12, 27	1/1/2024	\$10.00	per administration	once per day
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	33	335	11, 12, 27	1/1/2024	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	01	183	22	10/1/2023	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	08	082	49	10/1/2023	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	09	All	11, 12, 27	10/1/2023	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	10	100	11, 12, 27	10/1/2023	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	24	247	11	10/1/2023	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	31	All	11, 12, 27	10/1/2023	\$10.00	per administration	once per day
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use Zaire ebolavirus vaccine, live, for	33	335	11, 12, 27	10/1/2023	\$10.00	per administration	once per day
90758	intramuscular use Zaire ebolavirus vaccine, live, for	01	183	22	10/1/2023	\$10.00	per administration	once per day
90758	intramuscular use Zaire ebolavirus vaccine, live, for	08	082	49	10/1/2023	\$10.00	per administration	once per day
90758	intramuscular use	09	All	11, 12, 27	10/1/2023	\$10.00	per administration	once per day

	Zaire ebolavirus vaccine, live, for						per	once per
90758	intramuscular use	10	100	11, 12, 27	10/1/2023	\$10.00	administration	day
	Zaire ebolavirus vaccine, live, for						per	once per
90758	intramuscular use	24	247	11	10/1/2023	\$10.00	administration	day
	Zaire ebolavirus vaccine, live, for						per	once per
90758	intramuscular use	31	All	11, 12, 27	10/1/2023	\$10.00	administration	day
	Zaire ebolavirus vaccine, live, for						per	once per
90758	intramuscular use	33	335	11, 12, 27	10/1/2023	\$10.00	administration	day